cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.2908/tsc00010
title: High-tech patent applications to the European patent office (EPO) by priority year
title: Demandes de brevets de haute technologie déposées auprès de l'office européen des brevets (OEB) par année de priorité
title: Hochtechnologie-Patentanmeldungen beim Europäischen Patentamt (EPA) nach Prioritätsjahr

description: Die Daten beziehen sich auf den Anteil der Patentanmeldungen im Bereich der Spitzentechnologie je 1 Mio. Einwohner eines Landes, die direkt beim Europäischen Patentamt (EPA) eingereicht werden oder bei denen das EPA gemäß dem Patentzusammenarbeitsvertrag als Adressat benannt wird (Euro-PCT). Für die Definition der Patentanmeldungen im Bereich der Spitzentechnologie werden spezifische Unterklassen der Internationalen Patentklassifikation (IPK) benutzt, die im Trilateralen Statistischen Bericht von EPA, JPO und USPTO definiert sind.
description: The data refers to the ratio of patent applications made directly to the European Patent Office (EPO) or via the Patent Cooperation Treaty and designating the EPO (Euro-PCT), in the field of high-technology patents per million inhabitants of a country. The definition of high-technology patents uses specific subclasses of the International Patent Classification (IPC) as defined in the trilateral statistical report of the EPO, JPO and USPTO.
description: Les données font référence au pourcentage de brevets déposés directement auprès de l'Office européen des brevets (OEB) ou par le biais du traité de coopération en matière de brevets et désignant l'OEB (Euro-PCT) dans le domaine des brevets des technologies de pointe par millions d'habitants dans un pays. La définition des brevets des technologies de pointe utilise les sous-catégories spécifiques de la classification internationale des brevets (CIB) telles qu'elles sont définies dans le rapport statistique trilatéral de l'OEB, du JPO (Japan Patent Office) et de l'USPTO.
DOI: 10.25934/pr00006095.1
title: Available IPD datapackage for study 'Study 200977: Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine in the Treatment of Subjects With Type 2 Diabetes Mellitus: The Switch Study'

description: This Phase IIIb, randomized, open-label, parallel group, active control, multicenter, treat to-target study of 26 weeks' treatment duration will evaluate the efficacy and safety of once-weekly albiglutide as replacement of prandial insulin in subjects with type 2 diabetes mellitus (T2DM) failing to achieve adequate glycemic control on their current basal bolus insulin regimen (with or without metformin). Approximately 794 subjects will be randomly assigned in a 1:1 ratio to 1 of 2 treatment groups: albiglutide + insulin glargine (with insulin lispro discontinuation at Week 4) (with or without metformin) or to intensification of insulin glargine + insulin lispro (with or without metformin). The study will comprise 4 study periods : Screening (2 weeks), Standardization (4 weeks), Treatment (26 weeks), and Post treatment Follow up (4 weeks). The total duration of a subject's participation will be approximately 36 weeks.
DOI: 10.5281/zenodo.8154832
title: Supplementary material of the study "Help! I need somebody. A Mapping Study about Expert Identification in Software Development"

description: <strong>Supplementary Material</strong> <em><strong>Context</strong></em>: Software development is a knowledge-intensive activity, and its success in an organization relies deeply on knowledge sharing. Knowledge management challenges are often increased in agile environments, which involve a lot of tacit knowledge, commonly acquired through experiences and hard to be made explicit. Therefore, knowledge sharing among practitioners is crucial. However, identifying suitable experts to share specific knowledge is not trivial. It involves not only discovering the individuals with the desired knowledge but also considering other factors that may improve the expert responsiveness, such as social connections and availability. <em><strong>Objective</strong></em>: Considering the important role experts play in knowledge sharing, we decided to investigate approaches that help identify experts that can share knowledge in software development. Our goal is to provide a panorama of the existing approaches and shine a light on research opportunities. <em><strong>Method</strong></em>: We carried out a systematic literature mapping and analyzed 17 publications. <em><strong>Results</strong></em>: The results show that most approaches have relied on code repositories as a source of evidence for identifying experts and, consequently, focus on supporting developers and aiding in the codification activity. Additionally, expert identification has been mostly automated, and factors beyond possessing the desired knowledge have often been disregarded. <em><strong>Conclusion</strong></em>: Although there are several expert identification approaches, there has been a lack of concern with factors that influence reaching the most suitable expert for a specific situation (e.g., considering the characteristics of the person seeking knowledge). Moreover, there is a need for deeper reflection on how to better explore different artifacts as sources of expert evidence and how to combine them to improve expert identification. This package contains supplementary material of the study performed to investigate approaches that help identify experts that can share knowledge in software development. It contains: A spreadsheet containing raw data (research protocol, considered and selected publications, and research questions answers).
description: This research is funded in part by the Espírito Santo Research and Innovation Support Foundation (FAPES).
DOI: 10.25934/pr00001203.1
title: Available IPD datapackage for study 'A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects With Type 2 Diabetes Mellitus'

description: This study is designed to examine the efficacy and safety of 2 dose levels of weekly subcutaneously injected albiglutide compared with placebo and an open label reference arm of daily subcutaneous injections of liraglutide, in Japanese subjects with Type 2 diabetes mellitus.
DOI: 10.2908/tgs00040
title: Patent applications to the European patent office (EPO) by priority year by NUTS 2 regions
title: Demandes de brevets déposées auprès de l'office européen des brevets (OEB) par année de priorité, par région NUTS 2
title: Patentanmeldungen beim Europäischen Patentamt (EPA) nach Prioritätsjahr, nach NUTS-2-Regionen

description: Die Daten beziehen sich auf Patentanträge, die entweder direkt oder nach dem Vertrag über die internationale Zusammenarbeit auf dem Gebiet des Patentwesens beim EPA eingereicht wurden (Euro-PCT). Patentanträge werden in dem Jahr gezählt, in welchem sie beim EPA registriert wurden, und sind mittels der Internationalen Patentklassifikation klassifiziert. Die geographische Zuordnung erfolgt anhand des Wohnsitzes des Erfinders, wobei im Falle von mehreren Erfindern oder mehrerer IPK-Klassen eine anteilige Zählung vorgenommen wurde, um Mehrfachzählungen zu vermeiden. zu schreiben.
description: Data refer to applications filed directly under the European Patent Convention or to applications filed under the Patent Co-operation Treaty and designated to the EPO (Euro-PCT). Patent applications are counted according to the year in which they were filed at the EPO and are broken down according to the International Patent Classification (IPC). They are also broken down according to the inventor's place of residence, using fractional counting if multiple inventors or IPC classes are provided to avoid double counting.
description: Les données se rapportent aux demandes enregistrées directement dans le cadre de la convention sur le brevet européen ou aux demandes enregistrées dans le cadre du Traité de coopération en matière de brevets désignant l'OEB (Euro-PCT). Les demandes de brevet sont comptées en fonction de l'année au cours de laquelle elles sont enregistrées au niveau de l'OEB et réparties selon la classification internationale des brevets (IPC). Elles sont aussi réparties en fonction du lieu de résidence de l'inventeur. On utilise un comptage fractionnaire en cas de plusieurs inventeurs ou de plusieurs classes IPC afin d'éviter le double comptage.
DOI: 10.2908/tgs00041
title: High-tech patent applications to the European patent office (EPO) by priority year by NUTS 2 regions
title: Demandes de brevets de haute technologie déposées auprès de l'office européen des brevets (OEB) par année de priorité, par région NUTS 2
title: Hochtechnologie-Patentanmeldungen beim Europäischen Patentamt (EPA) nach Prioritätsjahr, nach NUTS-2-Regionen

description: Die Daten beziehen sich auf den Anteil der Patentanmeldungen im Bereich der Spitzentechnologie je 1 Mio. Einwohner eines Landes, die direkt beim Europäischen Patentamt (EPA) eingereicht werden oder bei denen das EPA gemäß dem Patentzusammenarbeitsvertrag als Adressat benannt wird (Euro-PCT). Für die Definition der Patentanmeldungen im Bereich der Spitzentechnologie werden spezifische Unterklassen der Internationalen Patentklassifikation (IPK) benutzt, die im Trilateralen Statistischen Bericht von EPA, JPO und USPTO definiert sind.
description: The data refers to the ratio of patent applications made directly to the European Patent Office (EPO) or via the Patent Cooperation Treaty and designating the EPO (Euro-PCT), in the field of high-technology patents per million inhabitants of a region. The definition of high-technology patents uses specific subclasses of the International Patent Classification (IPC) as defined in the trilateral statistical report of the EPO, JPO and USPTO.
description: Les données font référence au pourcentage de brevets déposés directement auprès de l'Office européen des brevets (OEB) ou par le biais du traité de coopération en matière de brevets et désignant l'OEB (Euro-PCT) dans le domaine des brevets des technologies de pointe par millions d'habitants dans un pays. La définition des brevets des technologies de pointe utilise les sous-catégories spécifiques de la classification internationale des brevets (CIB) telles qu'elles sont définies dans le rapport statistique trilatéral de l'OEB, du JPO (Japan Patent Office) et de l'USPTO.
DOI: 10.2908/tsc00009
title: Patent applications to the European patent office (EPO) by priority year
title: Demandes de brevets déposées auprès de l'office européen des brevets (OEB) par année de priorité
title: Patentanmeldungen beim Europäischen Patentamt (EPA) nach Prioritätsjahr

description: Die Gesamtzahl der europäischen Patentanmeldungen bezieht sich auf die Anträge auf den Schutz einer Erfindung, die entweder direkt beim Europäischen Patentamt (EPA) eingereicht werden oder bei denen das EPA gemäß dem Patentzusammenarbeitsvertrag als Adressat benannt wird (Euro-PCT); dabei spielt es keine Rolle, ob dem Antrag stattgegeben wird. Die Daten geben die Gesamtzahl der Anmeldungen je Land an. Wenn eine Anmeldung mehr als einen Erfinder hat, wird die Anmeldung gleichmässig auf die Erfinder aufgeteilt, und damit auf die Länder, in denen die Erfinder wohnhaft sind. Damit werden Mehrfachzählungen vermieden.
description: The total European patent applications refer to requests for protection of an invention directed either directly to the European Patent Office (EPO) or filed under the Patent Cooperation Treaty and designating the EPO (Euro-PCT), regardless of whether they are granted or not. The data shows the total number of applications per country. If one application has more than one inventor, the application is divided equally among all of them and subsequently among their countries of residence, thus avoiding double counting.
description: Le total des dépôts de brevets européens correspond aux demandes de protection d'une invention adressée soit directement à l'Office européen des brevets (OEB), soit classée dans le cadre du traité de coopération en matière de brevets et désignant l'OEB (Euro-PCT), qu'ils aient été accordés ou non. Les données indiquent le nombre total de demandes par pays. Si une demande a plus d'un inventeur, elle est divisé en part égale entre chaque inventeur et dans un deuxième temps, entre leur pays de résidence, ceci afin d'éviter un double comptage.
DOI: 10.6084/m9.figshare.23674506
title: Supplementary Date 7.12.docx

description: High fat diet.
DOI: 10.6084/m9.figshare.23674506.v3
title: Supplementary Date 7.12.docx

description: High fat diet.
DOI: 10.6084/m9.figshare.23674506.v2
title: Supplementary Date 7.12.docx

description: High fat diet.
DOI: 10.25345/c55q4rx1h
title: MassIVE MSV000092454 - Raw mass spectrometry data about the existence of most peptide segments of CYTB-187AA in five cell lines and the identification of CYTB-187AA interacting proteins
title: The existence of most peptide segments of CYTB-187AA to high confidence in five cell lines using mass spectrometry and the identification of CYTB-187AA interacting proteins.
DOI: 10.6084/m9.figshare.20377264
title: Structural modelling and <i>in silico</i> pharmacology of β-carboline alkaloids as potent 5-HT1A receptor antagonists and reuptake inhibitors

description: Serotonin (5-HT) antagonists and reuptake inhibitors (SARIs) are atypical antidepressants for managing major depressive disorder. They are oftentimes applied as adjuvants for ameliorating aftereffects of SSRI antidepressants including insomnia and sexual dysfunction. The few available candidates of this class including lorpiprazole and trazodone also display some daunting side effects, making a continuous search for improved alternatives essential. Natural β-carboline alkaloids (NβCs) are interestingly renowned with broad pharmacological spectrum against several neuropsychiatric disorders including depression. However, their potentials as SARIs remain underexplored. In this study, 982 NβCs retrieved from the Ambinter-Greenpharma (Amb) database were virtually screened for potent SARI alternatives using computational and biocheminformatics approaches: homology modelling of 5-HT1A receptor, Glide HTVS, SP and XP molecular docking, molecular dynamics (MD) simulation, ADMET and mutagenicity predictions. The homology receptor was validated as a good representative of human 5HT1A receptor using the RCSB structure validation and quality protocols. From the virtual screening against the 5-HT1A receptor, Amb ligands, <b>Amb18709727</b> and <b>Amb37857532</b> showed higher binding affinities by XP scores of −8.725 and −7.976 kcal/mol, and MMGBSA of −87.972 and −107.585 kcal/mol respectively compared to <b>lorpiprazole,</b> a reference SARI with XP score and MMGBSA of −6.512 and −62.788 kcal/mol respectively. They maintained ideal contacts with pharmacologically essential amino acid residues implicated in SARI mechanisms and expressed higher stability and compactness than lorpiprazole throughout the trajectories of 100 ns MD simulation. They also displayed interesting ADME, druggability, low toxicity and mutagenicity profiles, ideal for CNS drug prospects, thus, recommended as putative SARI candidates for further study. Communicated by Ramaswamy H. Sarma
DOI: 10.6084/m9.figshare.20377264.v1
title: Structural modelling and <i>in silico</i> pharmacology of β-carboline alkaloids as potent 5-HT1A receptor antagonists and reuptake inhibitors

description: Serotonin (5-HT) antagonists and reuptake inhibitors (SARIs) are atypical antidepressants for managing major depressive disorder. They are oftentimes applied as adjuvants for ameliorating aftereffects of SSRI antidepressants including insomnia and sexual dysfunction. The few available candidates of this class including lorpiprazole and trazodone also display some daunting side effects, making a continuous search for improved alternatives essential. Natural β-carboline alkaloids (NβCs) are interestingly renowned with broad pharmacological spectrum against several neuropsychiatric disorders including depression. However, their potentials as SARIs remain underexplored. In this study, 982 NβCs retrieved from the Ambinter-Greenpharma (Amb) database were virtually screened for potent SARI alternatives using computational and biocheminformatics approaches: homology modelling of 5-HT1A receptor, Glide HTVS, SP and XP molecular docking, molecular dynamics (MD) simulation, ADMET and mutagenicity predictions. The homology receptor was validated as a good representative of human 5HT1A receptor using the RCSB structure validation and quality protocols. From the virtual screening against the 5-HT1A receptor, Amb ligands, <b>Amb18709727</b> and <b>Amb37857532</b> showed higher binding affinities by XP scores of −8.725 and −7.976 kcal/mol, and MMGBSA of −87.972 and −107.585 kcal/mol respectively compared to <b>lorpiprazole,</b> a reference SARI with XP score and MMGBSA of −6.512 and −62.788 kcal/mol respectively. They maintained ideal contacts with pharmacologically essential amino acid residues implicated in SARI mechanisms and expressed higher stability and compactness than lorpiprazole throughout the trajectories of 100 ns MD simulation. They also displayed interesting ADME, druggability, low toxicity and mutagenicity profiles, ideal for CNS drug prospects, thus, recommended as putative SARI candidates for further study. Communicated by Ramaswamy H. Sarma
DOI: 10.6084/m9.figshare.20455641
title: Seasonal variation of the composition of essential oils from <i>Piper cernuum</i> Vell and <i>Piper rivinoides</i> Kunth, ADMET study, DFT calculations, molecular docking and dynamics studies of major components as potent inhibitors of the heterodimer methyltransferase complex NSP16-NSP10 SARS COV-2 protein

description: Coronavirus disease (COVID-19) has the virus that causes the SARS-CoV-2 severe acute respiratory syndrome, which has reached a pandemic proportion, with thousands of deaths worldwide already registered. It has no standardized effective clinical treatment, arousing the urgent need for the discovery of bioactive compounds for the treatment of symptoms of COVID-19. In this context, the present study aimed to evaluate the influence of seasonality on the yield and chemical composition of the essential oils of <i>Piper cernuum</i> and <i>Piper rivinoides</i> as well as to evaluate the anti-SARS-CoV-2 potential of the major components of each oil by molecular docking and quantum chemical calculation (Density Functional Theory method), being possible indicate that the winter and autumn periods, the seasons of the year where it is possible to obtain the highest percentage of <i>Piper cernuum</i> and <i>Piper rivinoides</i> oils, respectively. Regarding the anti-SARS-Cov-2 potential, the present work showed that the dihydroagarofuran present in <i>Piper cernuum</i>, presented a strong interaction with amino acid residues from Mpro, presenting a potential similar to Remdesivir, a drug for clinical use. Regarding methyltransferase, dihydroagarofuran (<i>Piper cernuum</i>) and myristicin (<i>Piper rivinoids</i>) showed better affinity, with important interactions at the active site of the inhibitor Sinefugin, suggesting a potential inhibitory effect of the heterodimer methyltransferase complex NSP16-NSP10 SARS Cov-2. Molecular docking and molecular dynamics studies represent an initial step, being indicative for future <i>in vitro</i> studies of dihydroagarofuran and myristicin, as possible pharmacological tools for COVID-19. Communicated by Ramaswamy H. Sarma Autumn and winter are the most suitable seasons of the year to extract the oils of <i>Piper rivinoides</i> and <i>Piper cernuum</i> respectively. <i>in silico</i> evaluation of majoritary compounds of essential oils against the anti-SARS-Cov-2 potential by Molecular docking. The electronic properties were computed using the Density Functional Theory method to understand the interaction of the molecules and the amino acids. Dihydroagarofuran (<i>Piper cernuum</i>) and myristicin (<i>Piper rivinoids</i>) suggesting a potential inhibitory effect of the heterodimer methyltransferase complex NSP16-NSP10 SARS Cov-2. Dihydroagarofuran present in <i>Piper cernuum</i> suggesting a potential inhibitory effect of the Mpro.
DOI: 10.6084/m9.figshare.20362911
title: Structure based virtual screening and molecular dynamics of natural anti-biofilm compounds against SagS response regulator/sensor kinase in <i>Pseudomonas aeruginosa</i>

description: SagS sensor regulator plays a vital role in biofilm development of <i>Pseudomonas aeruginosa</i> which subsequently makes the cells more tolerant to various antimicrobials. The multidrug resistance (MDR) issue has risen substantially in recent years and is considered a global threat. Therefore, alternative compounds should be unearthed immediately to address the issues related to <i>P. aeruginosa</i> drug resistance for which SagS could be a candidate. The present study is an attempt to screen natural anti-biofilm compounds as the potent inhibitors of SagS. Twenty natural anti-biofilm/quorum sensing inhibiting compounds were retrieved from various literatures with significant inhibitory effects against <i>P. aeruginosa</i> biofilm from <i>in-vitro</i> experiments which were screened using various pharmacokinetic parameters. The screened and three standard drugs were docked against SagS-HisKA using AutoDock 4.2 tool, which were further analysed by MD simulations to understand the binding mode of compounds and dynamic behaviour of the complexes. Two potential anti-biofilm natural compounds, pinocembrin with binding affinity (-7.19 kcal/mol), vestitol (-7.18 kcal/mol) and the standard drug ceftazidime (-8.89 kcal/mol) were selected based on filtered parameters and better binding affinity. The trajectory analysis of MD simulations reflected Pinocembrin in stabilizing the system compared to ceftazidime. The existing reports state that the natural products represent promising source of therapy with least or almost nil adverse effect compared to synthetic drugs which is well collated with our <i>in-silico findings</i>. This investigation can save both time and cost required for <i>in-vitro</i> and <i>in-vivo</i> analysis for designing of a novel anti-biofilm agent against <i>P. aeruginosa</i> biofilm-associated infections. Communicated by Ramaswamy H. Sarma